Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE

Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE

Abstract Background Consensus treatment plans have been developed for induction therapy of newly diagnosed proliferative lupus nephritis (LN) in childhood-onset systemic lupus erythematosus. However, patients who do not respond to initial therapy, or who develop renal flare after remission, warrant...

Full description

Bibliographic Details
Main Authors: Mileka Gilbert, Beatrice Goilav, Joyce J. Hsu, Paul J. Nietert, Esra Meidan, Annabelle Chua, Stacy P. Ardoin, Scott E. Wenderfer, Emily von Scheven, Natasha M. Ruth, for the Pediatric Nephrology and Rheumatology Collaborative Group, the Childhood Arthritis and Rheumatology Research Alliance, and the American Society for Pediatric Nephrology
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Juvenile systemic lupus erythematosus
Refractory lupus nephritis
Renal flare
Therapy choices
Pediatric rheumatologist
Pediatric nephrologist
Online Access:https://doi.org/10.1186/s12969-021-00627-w

Internet

https://doi.org/10.1186/s12969-021-00627-w

Similar Items